



सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health
Services) Ministry of Health & Family
Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-
23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/25/000039

To,

M/s Parexel International Clinical Research Private Limited,
CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A,
Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103

Sir,

With reference to your application No. GCT/CT04/FF/2025/49088 dated 21-Apr-2025, please find enclosed herewith the permission in Form CT-06 for conduct of **phase III** clinical trial titled, **“A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexamipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)”** Protocol No. AR-DEX-22-01, India Specific amendment 1 dated 03 March 2025 with a total of up-to 80 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- 1) **Carcinogenicity study report shall be submit once the study completed.**
- 2) **Human biological samples i.e. Whole blood, plasma, serum and urine related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.**
- 3) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- 4) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- 5) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- 6) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- 7) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- 8) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- 9) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- 10) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- 11) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- 12) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- 13) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- 14) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- 15) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- 16) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- 17) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- 18) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- 19) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- 20) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- 21) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licensing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. Parexel International Clinical Research Private Limited, CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A, Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103 Telephone No.: 8067723000 FAX: 80 67723001 E-Mail : PAREXELINDIA@PAREXEL.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No. AR-DEX-22-01, India Specific amendment 1 dated 03 March 2025** in the below mentioned clinical trial sites [As per Annexure].-
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licensing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Dexpramipexole dihydrochloride monohydrate
	Dexpramipexole dihydrochloride monohydrate
Therapeutic class:	Small molecule eosinophil lowering agent
	Small molecule eosinophil lowering agent
Dosage form:	Tablets
	Tablets
Composition:	Dexpramipexole (KNS-760704)=75.0000 milligram (mg) In House Specification Active
	Dexpramipexole (KNS-760704)=150.0000 milligram (mg) In House Specification Active
Indications:	Severe eosinophilic asthma
	Severe eosinophilic asthma

Annexure:

Details of clinical trial site:

S.No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Sir Ganga Ram Hospital, Sir Ganga Ram Hospital Marg, Rajinder Nagar, New Delhi 110060 India	Sir Ganga Ram Hospital Ethics Committee. Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi 110060 India. EC Re-Registration No. ECR/20/Inst/DL/2013/RR-24	Dr Ujjwal Kumar Parakh
2.	Shree Hospital and Critical Care Centre, 799, Om Nagar Opp. Tajshree Building, Sakkardara Sq. Nagpur-440009, Maharashtra, India	Shree Hospital Ethics Committee, Shree Hospital Unit, Plot No.786 A, 3rd Floor Behind Shree Hospital & Critical Care Centre, Mirchi Bazaar, Umrer Road, Sakkardara, S q, Nagpur 440009, Maharashtra, India. EC Re-Registration No. ECR/553/Inst/MH/2014/RR-20	Dr Akash Balki
3.	Belagavi Institute of Medical Sciences, Belagavi 3rd Floor, BIMS Building, Clinical, Research Department, Dr B.R.	Institutional Ethics Committee Belagavi Institute of Medical Sciences (BIMS), Belagavi, 3rd floor, BIMS building Department of community medicine Dr B.R.	Dr Sandeep Dandin

	Ambedkar Road, Belagavi - 590001, Karnataka, India.	Ambedkar Road Belagavi- 590001, Karnataka, India. EC Re-Registration No. ECR/801/Inst/KA/2016/RR-20	
4.	MV Hospital And Research Centre, 314/30, Mirza Mandi Chowk Lucknow- Uttar Pradesh Lucknow Uttar Pradesh -226003	Institutional Ethics Committee for M. V. Hospital and Research Centre, 1st Floor, 314/30, Mirza Mandi, Chowk, Lucknow-226003, Uttar Pradesh, India. EC Re-Registration No. ECR/13/Inst/UP/2013/RR-24	Dr Sandeep Kumar Gupta
5.	Divine Multispeciality Hospital, 2nd-3rd Floor, Shikshapatri SkyCourt, Near Swagat Flamingo, Sargasan, Gandhinagar Gujarat - 382421	Divine Ethics Committee, Divine Multispeciality Hospital, 2nd-3rd Floor, Shikshapatri Sky Court, Near Swagat Flamingo, Sargasan, Gandhinagar-382421, India. EC Re-Registration No. ECR/1731/INST/GJ/2022	Dr Zalak Mahendrakumar Asodiya
6.	Murarilal Chest Hospital, GSVM Medical College, Swaroop Nagar, Kanpur Uttar Pradesh - 208002	Ethics Committee GSVM Medical College, Swaroop Nagar, Kanpur-208002, Uttar Pradesh, India. EC Re-Registration No. ECR/680/Inst/UP/2024/RR-20	Dr Sanjay Kumar Verma
7.	Dept of Pulmonary and Critical care Medicine, Pt. B.D Sharma Post Graduate Institute of Medical Sciences Rohtak-124001, Haryana, India.	Institutional Ethics Committee, PGIMS UHS Rohtak Pt. BD Sharma, Post Graduate Institute of Sciences PGIMS UHS Rohtak-124001 Haryana - 124001 India. EC Re-Registration No. ECR/293/Inst/HR/2013/RR-24	Dr Pawan Kumar Singh
8.	SDS TRC and Rajiv Gandhi Institute of Chest Diseases, 1 st Main Road, Near NIMHANS Hospital, Someshwar Nagar, Bangalore Karnataka - 560029	SDS TRC And RGICD 1st Floor Administrative Block 1st Main Someshwara Nagar DC Post, Near NIMHANS Campus Bangalore Bengaluru Urban Karnataka 560029 India. EC Re-Registration No. ECR/1700/Inst/KA/2022	Dr Akshata JS

9.	Sardar Patel Medical College and A.G. Hospitals, Department of Respiratory, Sardar Patel colony, Bikaner 334003, Bikaner Rajasthan - 334003	Ethics Committee, SP medical College and A.G. Hospitals, Bikaner 334003, Rajasthan, India. EC Re-Registration No. ECR/27/SP/INST/RJ/2013/RR-19	Dr Pramod Thakral
10.	Government Medical College and Government General Hospital, Department of Pulmonology, OPD No. 14, 1 st Floor Srikakulam Andhra Pradesh - 532001	Institutional Ethics Committee Govt. Medical College and Govt. General Hospital Balaga Srikakulam, Andhra Pradesh, India. EC Re-Registration No. ECR/492/Inst/AP/2013/RR-20	Dr Ravi Koppula
11.	Assured Care Plus Hospital, 4th and 5th Floor, Star Plus Complex, Lam Road, Near Muktidham Temple Opp. NMC Divisional Office, Nashik Road, Nashik Maharashtra	Institutional Ethics Committee Assured Care Plus Hospital 4th And 5th Floor Star Plus Complex Lam Road, Near Muktidham Temple, Opp. NMC Divisional Office, Nashik Road, Nashik, Maharashtra - 422101 India. EC Re-Registration No. ECR/1756/Inst/MH/2022	Dr Vijay Popatlal Surana
12.	Eras Bharti Hospital, Ganesham Commercial A Building, Floor 3rd and 4th, Near Govind Yashda Chowk, BRT Link Road, Pimple Saudagar Pune Maharashtra -411027	Saikrupa Hospital Institutional Ethics Committee, Saikrupa Hospital, Renuka Corner, Tapkir Chowk, Thergaon, Pune 411033, Maharashtra, India. EC Re-Registration No. ECR/1350/Inst/MH/2020	Dr Rajkumar Nikalje
